Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide and Rosiglitazone in Type 2 Diabetes
NCT00135330Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Primary completion
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2005; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00135330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135330.